Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial.
Mulder EEAP, de Joode K, Litière S, Ten Tije AJ, Suijkerbuijk KPM, Boers-Sonderen MJ, Hospers GAP, de Groot JWB, van den Eertwegh AJM, Aarts MJB, Piersma D, van Rijn RS, Kapiteijn E, Vreugdenhil G, van den Berkmortel FWPJ, Hoop EO, Franken MG, Ryll B, Rutkowski P, Sleijfer S, Haanen JBAG, van der Veldt AAM. Mulder EEAP, et al. Among authors: aarts mjb. BMC Cancer. 2021 Mar 25;21(1):323. doi: 10.1186/s12885-021-08018-w. BMC Cancer. 2021. PMID: 33765967 Free PMC article.
Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation.
Badrising SK, van der Noort V, van den Eertwegh AJ, Hamberg P, van Oort IM, van den Berg HP, Los M, Aarts MJ, Coenen JL, Gelderblom H, de Jong IJ, Kerver ED, Vrijaldenhoven S, van Voorthuizen T, Warmerdam F, Haanen JB, Bergman AM; Dutch Uro-Oncology Studygroup. Badrising SK, et al. Prostate. 2016 Jan;76(1):32-40. doi: 10.1002/pros.23094. Epub 2015 Sep 22. Prostate. 2016. PMID: 26390914
Ultrasound is at least as good as magnetic resonance imaging in predicting tumour size post-neoadjuvant chemotherapy in breast cancer.
Vriens BE, de Vries B, Lobbes MB, van Gastel SM, van den Berkmortel FW, Smilde TJ, van Warmerdam LJ, de Boer M, van Spronsen DJ, Smidt ML, Peer PG, Aarts MJ, Tjan-Heijnen VC; INTENS Study Group. Vriens BE, et al. Eur J Cancer. 2016 Jan;52:67-76. doi: 10.1016/j.ejca.2015.10.010. Epub 2015 Nov 30. Eur J Cancer. 2016. PMID: 26650831 Clinical Trial.
Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer.
Badrising SK, van der Noort V, Hamberg P, Coenen JL, Aarts MJ, van Oort IM, van den Eertwegh AJ, Los M, van den Berg HP, Gelderblom H, Vrijaldenhoven S, Kerver ED, van Voorthuizen T, de Jong IJ, Haanen JB, Bergman AM; Dutch Uro-Oncology Study Group (DUOS). Badrising SK, et al. Oncology. 2016;91(5):267-273. doi: 10.1159/000448219. Epub 2016 Aug 20. Oncology. 2016. PMID: 27544669
Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer: The ROPETAR Randomized Clinical Trial.
Cirkel GA, Hamberg P, Sleijfer S, Loosveld OJL, Dercksen MW, Los M, Polee MB, van den Berkmortel F, Aarts MJ, Beerepoot LV, Groenewegen G, Lolkema MP, Tascilar M, Portielje JEA, Peters FPJ, Klümpen HJ, van der Noort V, Haanen JBAG, Voest EE; Dutch WIN-O Consortium. Cirkel GA, et al. JAMA Oncol. 2017 Apr 1;3(4):501-508. doi: 10.1001/jamaoncol.2016.5202. JAMA Oncol. 2017. PMID: 27918762 Clinical Trial.
Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands.
Jochems A, Schouwenburg MG, Leeneman B, Franken MG, van den Eertwegh AJ, Haanen JB, Gelderblom H, Uyl-de Groot CA, Aarts MJ, van den Berkmortel FW, Blokx WA, Cardous-Ubbink MC, Groenewegen G, de Groot JW, Hospers GA, Kapiteijn E, Koornstra RH, Kruit WH, Louwman MW, Piersma D, van Rijn RS, Ten Tije AJ, Vreugdenhil G, Wouters MW, van der Hoeven JJ. Jochems A, et al. Eur J Cancer. 2017 Feb;72:156-165. doi: 10.1016/j.ejca.2016.11.021. Epub 2016 Dec 25. Eur J Cancer. 2017. PMID: 28030784
Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer.
Vriens BEPJ, Vriens IJH, Aarts MJB, van Gastel SM, van den Berkmortel FWPJ, Smilde TJ, van Warmerdam LJC, van Spronsen DJ, Peer PGM, de Boer M, Tjan-Heijnen VCG; Breast Cancer Trialists’ Group of the Netherlands (BOOG). Vriens BEPJ, et al. Among authors: aarts mjb. Breast Cancer Res Treat. 2017 Oct;165(3):593-600. doi: 10.1007/s10549-017-4364-8. Epub 2017 Jul 3. Breast Cancer Res Treat. 2017. PMID: 28674765 Free PMC article. Clinical Trial.
Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands.
Franken MG, Leeneman B, Jochems A, Schouwenburg MG, Aarts MJB, van Akkooi ACJ, van den Berkmortel FWPJ, van den Eertwegh AJM, de Groot JWB, van der Hoeven KJM, Hospers GAP, Kapiteijn E, Koornstra R, Kruit WHJ, Louwman MWJ, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, Vreugdenhil G, Wouters MWJM, van Zeijl M, Haanen JBAG, Uyl-de Groot CA. Franken MG, et al. Among authors: aarts mjb. Anticancer Drugs. 2018 Jul;29(6):579-588. doi: 10.1097/CAD.0000000000000628. Anticancer Drugs. 2018. PMID: 29634490
Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands.
Jochems A, Leeneman B, Franken MG, Schouwenburg MG, Aarts MJB, van Akkooi ACJ, van den Berkmortel FWPJ, van den Eertwegh AJM, Groenewegen G, de Groot JWB, Haanen JBAG, Hospers GAP, Kapiteijn E, Koornstra RH, Kruit WHJ, Louwman MWJ, Piersma D, van Rijn RS, Ten Tije AJ, Vreugdenhil G, Wouters MWJM, Uyl-de Groot CA, van der Hoeven KJM. Jochems A, et al. Among authors: aarts mjb. Anticancer Drugs. 2018 Jul;29(6):572-578. doi: 10.1097/CAD.0000000000000629. Anticancer Drugs. 2018. PMID: 29659371
Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes.
Schouwenburg MG, Jochems A, Leeneman B, Franken MG, van den Eertwegh AJM, Haanen JBAG, van Zeijl MCT, Aarts MJ, van Akkooi ACJ, van den Berkmortel FWPJ, Blokx WAM, de Groot JWB, Hospers GAP, Kapiteijn E, Koornstra RH, Kruit WH, Louwman MWJ, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, Vreugdenhil G, Wouters MWJM, van der Hoeven JJM. Schouwenburg MG, et al. Melanoma Res. 2018 Aug;28(4):326-332. doi: 10.1097/CMR.0000000000000453. Melanoma Res. 2018. PMID: 29750749
152 results